Instituto de Oncologia Ángel H. Roffo, Av. San Martín 5481, Buenos Aires, Argentina.
Curr Pharm Biotechnol. 2011 Nov;12(11):1937-47. doi: 10.2174/138920111798377085.
Matrix metalloproteinases (MMPs) have been implicated in both normal and pathologic processes. In cancer in particular, in vitro and animal studies showed an involvement of MMPs in many stages of cancer progression. This led to the development of MMP inhibitors that in most cases failed in clinical trials. In this review we go over the role of MMPs in the different stages of cancer progression and try to understand why the early generation of MMP inhibitors failed. The analysis of the lessons from this first experience, plus the review of the current knowledge that shows that MMPs may be pro-or anti-tumorigenic may set the stage for a future success for this therapeutic strategy in cancer.
基质金属蛋白酶（MMPs）与正常和病理过程都有关联。在癌症中，体外和动物研究表明 MMPs 参与了癌症进展的许多阶段。这导致了 MMP 抑制剂的开发，但在大多数情况下，这些抑制剂在临床试验中都失败了。在这篇综述中，我们回顾了 MMPs 在癌症进展的不同阶段中的作用，并试图了解为什么第一代 MMP 抑制剂失败了。对这一最初经验的教训进行分析，加上对当前知识的回顾，表明 MMPs 可能具有促进或抑制肿瘤发生的作用，这可能为这种癌症治疗策略的未来成功奠定基础。
